Plasma membranes derived from a rat thyroid tumor (1-8R) which is unresponsive to thyrotropin but is responsive to dibutyryl adenosine 3':5'-cyclic monophosphate bind less than 20% of the [25#Ithyrotropin which can be bound to plasma membranes from normal rat thyroids under conditions which optimize tumor membrane binding relative to normal thyroid membranes. In addition, the binding is different from thyrotropin binding to normal thyroid membranes both in its altered sensitivity to changes in hydrogen ion concentration and in a decreased sensitivity to competition by unlabeled Galactosyl-N-acetylgalactosaminyl[N-acetylneuraminylJgalactosylglucosylceramide can also be detected in normal membranes, but not in tumor membranes, by selective labeling with galactose oxidase (D-galactose:oxygen 6-oxidoreductase, EC 1.1.3.9) and [3H]sodium borohydride. These results support the hypothesis that gangliosides are important structural or functional components of thyrotropin receptors on thyroid plasma membranes.
to plasma membranes from normal rat thyroids under conditions which optimize tumor membrane binding relative to normal thyroid membranes. In addition, the binding is different from thyrotropin binding to normal thyroid membranes both in its altered sensitivity to changes in hydrogen ion concentration and in a decreased sensitivity to competition by unlabeled thyrotropin. This reduced capacity to bind ['25I]thyrotropin cannot be attributed to degradation of the hormone by membrane-associated proteases. Although the supernatant phase of the thyroid tumor homogenates contains a soluble component which inhibits [125Isthyrotropin binding to thyrotropin receptors on plasma membranes, its level is the same as in homogenates of normal thyroid tissue. Trypsin digestion does not expose thyrotropin receptors in a manner analogous to that seen in normal thyroid tissue. The major ganglioside in the tumor membranes is N-acetylneuraminylgalactosylglucosylceramide and the membranes lack the N-acetylgalactosaminyltransferase required for the synthesis of more complex gangliosides. In contrast, the normal rat thyroid membranes Recently we reported that gangliosides could inhibit the binding of thyrotropin (TSH) to bovine thyroid membranes (1) and suggested that the mechanism by which TSH transmits its message to the thyroid cell has certain analogies to that of cholera toxin (1) (2) (3) (4) The tumors were collected approximately 2 months after subcutaneous implantation when they had attained an average weight of 5 g, and they were kept at 1°until used. Data concerning the histology, the growth rate, and some metabolic properties of this tumor have been previously reported (5-9). Control thyroids were taken from nontumor-bearing Fischer rats.
Plasma membranes were prepared from normal thyroid and rat thyroid tumors with procedures described for the isolation of bovine thyroid plasma membranes, all procedures being performed at 0-2°(10, 13). Cell sap is the 105,000 X g supernatant after a 90 min centrifugation from either normal thyroid or the 1-8R tumor homogenized with nine volumes of ice-cold 0.01 M Tris-acetate buffer at pH 7.0 (15) .
Gangliosides were extracted from normal and tumor thyroid membranes, purified, separated by thin-layer chromatography, and visualized with resorcinol reagent as previously described (1). The procedure for labeling ganglioside in intact membranes with galactose oxidase (D-galactose:oxygen 6-oxidoreductase, EC 1.L3.9) and NaB[3H]4 has been described in an earlier report (2) . Activities of glycosyltransferases involved in ganglioside biosynthesis were determined either in whole homogenates or partially purified membrane preparations by means of established procedures (16, 17) . The pH optimum of 125I-labeled TSH binding to the plasma membranes from the two preparations was significantly different (Fig. 1) . 125I-Labeled TSH binding to the normal thyroid plasma membranes was biphasic and showed pH maxima at both 5.5 and 7.8. In contrast, the tumor binding showed no maxima at 7.8, but did improve relative to the normal thyroid membranes at higher hydrogen ion concentrations. As reported for bovine thyroid membranes (10, 20) , 125I-labeled TSH binding to the thyroid tumor membranes at pH 7.5 was improved at 40 rather than 230 (data not shown). The 125I-labeled TSH binding to the normal rat thyroid plasma membranes had a different temperature optimum, i.e., had improved binding at 230 rather than 40 (Table 1) . Nevertheless, even under conditions which optimized the 125I-labeled TSH binding to the tumor membranes relative to normal membranes (a 1 hr incubation at 40 in 0.02 M Tris-acetate at pH 6.0), '25I-labeled TSH binding to the tumor membranes was significantly reduced ( Table 1) . Binding of TSH to both normal and tumor membranes were inhibited by mono-and divalent cations; however, binding to tumor membranes was more sensitive to divalent cations.
Binding of 125I-labeled TSH to normal rat thyroid membranes was readily blocked by unlabeled TSH, whereas, in accord with previous findings (9), the low level of 125-Ilabeled TSH binding to the thyroid tumor was less inhibited under these same experimental conditions (Table 2) . l25I-Labeled TSH binding to the normal and tumor rat thyroid membranes both (9) . Because the inability of the thyroid tumor membranes to bind TSH might be due to degradation of TSH by membrane-associated proteases, unlabeled TSH was preincubated in the presence of 0.25% bovine serum albumin (to make the ratio of soluble protein to membranes equivalent to that of the binding assay) with the 1-8R tumor membrane or with normal bovine thyroid membranes or Tris-acetate buffer at pH 7.0, as controls. After centrifugation at 25,000 X g for 10 min, the supernatant phase containing the cold hormone was collected and used to inhibit the '25I-labeled TSH binding to bovine thyroid plasma membranes. All three TSH preparations displayed almost identical inhibitory action.
As previously shown with bovine thyroid membranes (20) , treatment with trypsin causes a loss in receptor binding activity Membranes were exposed to L-1-tosylamino-2-phenylethylchloromethyl ketone trypsin at room temperature for 2 hr at a 14.8:1 ratio of membranes to trypsin (wt/wt) in Tris-acetate buffer at pH 7.0. At the end of the incubation period, the membranes were mixed with an amount of cold soybean trypsin inhibitor 5-fold in excess of the trypsin concentration, and the suspension was chilled to 2-4° (13, 20) . The suspension was immediately assayed for binding activity in optimal assay conditions at pH 6 .0 and at 7.5 nM 1251-labeled TSH concentration. After the binding assay was performed, 4% polyethylene glycol 6000 was added and the suspension was filtered. Binding in the presence of polyethylene glycol measures the membrane receptor activity plus the receptor activity solubilized by the preincubation conditions (13) . Tables 2 and 3. on the plasma membranes but releases receptor binding activity into the supernatant phase. Trypsin treatment of normal rat or normal bovine thyroid membranes results in the release of soluble receptor activity into the supernatant phase and in an increase in total receptor activity as assayed using a technique which will simultaneously measure both membrane-bound and soluble binding activity (Table 3 ). In contrast, the trypsinization of 1-8R tumor membranes (a) causes a loss of membrane-associated binding activity (Table 4 ) and (b) does not release soluble binding activity into the supernatant phase by comparison to identical incubations without trypsin. These data show that trypsin digestion of 1-8R tumor membranes does not expose or release TSH receptors in a manner analogous to that seen in normal thyroid tissue. The supernatant phase of the thyroid homogenates contains a soluble TSH binding component which inhibits 125I-labeled TSH binding to TSH receptors on plasma membranes both from bovine thyroid and from guinea pig retro-orbital tissue (15) . As shown in Table 4 , the supernatant phase of the 1-8R tumor homogenates contained such a soluble TSH binding component; however, no striking differences in the amount of the soluble binding component present in the cell sap were noted between tumor and normal TSH binding preparations.
Ganglioside Composition and Ganglioside Synthesis in Membrane Preparations from Normal Rat Thyroid and from 1-SR Tumor Thyroids. Gangliosides were extracted from normal rat and tumor thyroid membranes, purified, and analyzed by thin-layer chromatography (Fig. 2) . The major gangliosides isolated from the tumor membranes had the same mobility as authentic N-acetylneuraminylgalactosylglucosylceramide (GM3) (Fig. 2A ). There were only trace amounts of gangliosides with slower mobilities on the chromatogram. In contrast, gangliosides corresponding to GM3, GM1, and N-acetylneuraminylgalactosyl-N-acetylgalactosaminyl-[Nacetylneuraminyl]-galactosylglucosylceramide (GMa) were isolated from normal rat thyroid membranes (Fig. 2B) . When ganglioside fractions isolated from normal and tumor membranes were incubated with purified bacterial neuraminidase (21) and chromatographed, over 95% of the GM3 from the tumor membranes had disappeared, and bands corresponding to lactosylceramide had appeared on the chromatogram. This procedure further identified the major ganglioside in the tumor membranes as GM3. After neuraminidase treatment the only ganglioside remaining in the normal thyroid extract corresponded to GM1. This result supported the identification of the predominant gangliosides in these membranes as GM3, GM1, and GDla (1) .
In a previous report we showed that the terminal galactose residue of the carbohydrate moiety in the ganglioside GM1 of bovine thyroid membranes can be tritiated by sequential treatment with galactose-oxidase and 3H-labeled sodium borohydride (2) . When normal rat thyroid membranes were incubated with galactose oxidase and exposed to 3H-labeled sodium borohydride, tritium was incorporated into GM1 residues (Fig. 3) . In contrast, when the 1-8R tumor membranes were similarly treated, no radioactive peaks corresponding to ganglioside GM1 were detected after scanning the chromato,-graphic plates (Fig. 3) .
As shown in Table 5 , the lack of gangliosides more complex than GM3 in the thyroid tumor plasma membranes was related to a defect of synthesis of N-acetylgalactosaminyl-[N-acetylneuraminyl]-galactosylglucosylceramide (GM2) from GM3 caused by the absence of UDP-GalNAc:GM3 N-acetylgalactosaminyltransferase. Concurrent with this enzyme defect, other enzymatic activities such as CMP-N-acetylneuraminyl:lactosylceramide sialyltransferase and the UDP-Gal:GM2 galactosyltransferase were depressed, whereas sialyltransferase II which catalyzes the synthesis of GDla from GM1 was drastically enhanced ( Table 5 ). All of these enzyme activities were readily detected in the normal rat thyroid, a result consistent with observed presence of gangliosides GM1 and GDIa in the normal membranes. There was a significant enrichment of these enzyme activities in the membrane preparations compared to the [3H]Ganglioside pattern in rat thyroid and tumor 1-8R plasma membranes after treatment with galactose oxidase and 3H-labeled sodium borohydride. Ten milligrams of membrane protein was treated with galactose oxidase (100 units) for 2 hr in phosphate buffered saline, pH 7.4, at 250 (2). One unit of activity equals an increase in absorbance of 1.00 per min when assayed according to the manufacturer, Worthington Biochemical Corp. The membranes were washed three times with 0.05 M Tris-acetate at'pH 7.8, resuspended in the same buffer, and then treated with 5 mCi of 3H-labeled sodium borohydride for 30 min. The labeled membranes were washed three times in 0.05 M Tris-acetate at pH 7.8, and the gangliosides were extracted (2) . The gangliosides were subjected to thin-layer chromatography, and the plates were scanned using a Varian radioscanning instrument (graphs). Simultaneous chromatography of authentic gangliosides allowed the identification of the peaks of radioactivity.
total homogenate. Subcellular fractionation of bovine thyroid gland indicates that these enzymes are localized in the Golgi apparatus, as there was a 20-to 50-fold enrichment of the various ganglioside glycosyltransferase activities (manuscript in preparation).
DISCUSSION
In the present report we show that even under conditions which optimized 125I-labeled TSH binding to the 1-8R tumor membranes, TSH receptor activity was significantly decreased in the tumor membranes, and what little 125I-labeled TSH binding activity could be detected was abnormal in its sensitivity to pH and cations and in its resistance to inhibition by unlabeled TSH. Further, the data showed (a) that the decreased receptor activity could not be attributed to degradation of TSH by membrane-associated proteases during the incubation period; (b) that trypsin digestion neither exposed TSH receptors which might have been buried in the plasma membrane nor released significant receptor activity into the supernatant phase; and (c) that the tumor preparation was not contaminated by the increased presence of a soluble TSH binding component present in the cytosol.
The rat tumor thyroid membranes lacked gangliosides more complex than GM3 and the N-acetylgalactosaminyltransferase necessary for their synthesis. In contrast, the normal rat thyroid membranes contained more complex gangliosides such as GM1 and GDla and the requisite ganglioside biosynthetic enzymes. Deficient ganglioside biosynthesis has been observed in many Cell Biology: Meldolesi et al. Table 5 . Activity of enzymes involved in the biosyntheticmalignant cells (22) , and a specific deficiency in this N-acetylgalactosaminyltransferase activity and gangliosides more complex than GM3 has been found in transformed mouse (22) , hamster (23) , and rat cells (24) .
In previous reports, we indicated that ganglioside could inhibit the binding of TSH to bovine thyroid membranes and the subsequent activation of adenylate cyclase and suggested that gangliosides or ganglioside-like structures may be part of the TSH receptor on these membranes (1, 2) . In addition, we demonstrated that cholera toxin and TSH could compete with one another for binding (presumably to GM1 receptors) (2). These GM1 molecules were exposed on the surface of membranes as they could be tritiated by the galactose oxidase-[3H]sodium borohydride procedure and specifically protected from tritiation by cholera toxin (2) . In a similar manner, we now show that GM1 residues are exposed on the membranes from normal rat thyroid but not from a rat thyroid tumor which is defective in TSH binding. Thus, at least one of the gangliosides implicated in TSH binding is absent from this tumor.
Previous studies indicated that a glycopeptide that has TSH binding ability could be released by trypsin or detergents from thyroid membranes (13, 20, 25) . Loss of this receptor component from thyroid membranes paralleled loss of TSH binding, adenylate cyclase stimulation, and TSH activity (13, 20, 25) . The material released by trypsin contains approximately 30% carbohydrate and 10% sialic acid; disc gel electrophoretic analysis indicated that the major protein and carbohydrate staining component has a molecular weight of 24,000 (13, 25) .
The present studies suggest that this TSH receptor component is either absent or defective in the tumor membranes since comparable material is not released from these membranes by trypsin (Table 3) . Preliminary data concerning the solubilization of 1-8R thyroid tumor membranes by lithium diiodosalicylate confirm this conclusion (unpublished data). The relationship between the above glycopeptide TSH receptor component and the gangliosides that are found in normal thyroid membranes and that bind TSH in vitro thus has yet to be determined. One possibility is that after binding to the glycopeptide component of the receptor, the TSH molecule interacts with a specific ganglioside and undergoes a conformational change which ultimately leads to changes in the state of the membrane, alterations in ion transport, and activation of adenylate cyclase. Absence of one or both of these receptor components would result in thyroid membrane unresponsive to TSH as observed in the rat thyroid tumor that we have investigated. We believe that additional studies of this tumor and its membranes should enhance still further our knowledge of the biosynthesis of TSH receptor components, of their integration in the membrane bilayer, and of the mechanism by which the receptor transmits its message through the membrane bilayer to cause adenylate cyclase stimulation.
